Status:
COMPLETED
Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Dyslipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
Eligibility Criteria
Inclusion
- African American men and women with concurrent hypertension and dyslipidemia that is either treated or untreated
- Subjects must satisfy the blood pressure and LDL-C inclusion criteria for their respective Cardiovascular Risk group determined at screening
Exclusion
- Subjects currently being treated with concomitant amlodipine and atorvastatin therapy, including Caduet
- Subjects with blood pressure at goal
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00150384
Start Date
July 1 2004
End Date
August 1 2005
Last Update
January 27 2021
Active Locations (106)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35211
3
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
4
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72204